TrialDrug design, development and therapy2018

Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.

Tom Ottoboni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.